Table 4.
Date | Study Size | Mean Population Age (Standard Deviation, When Provided) |
Gender | Percent of Outpatients with Persisting Symptoms |
Source |
---|---|---|---|---|---|
May 2020 | 350 | Median: 43 * | F: 53% M: 47% |
36% (14–21 days) | [81] |
March 2021 | 177 | 48 | F: 57.1% M: 42.9% |
32% (median: 169 days) | [80] |
April 2021 | 4182 | 45.97 (15.8) | F: 71.5% M: 28.5% |
13.3% (28+ days) | [13] |
July 2020 | 143 | 56.5 (14.6) | F: 37% M: 63% |
87.4% (Mean 60.3 days [SD: 13.6]) | [82] |
Sep 2021 | 106,578 | 39.4 (18.4) | F: 58.4% M: 41.6% |
36.55% (90–180 days) | [83] |
Feb 2022 | 5,080,312 | See source ** | F: 61.2% M: 38.8% |
35% (31–150 days) | [84] |
* Only the median age is provided in this study; ** Mean age of study participants was not provided in this study. However, study participants were categorized as older or younger than 20 years of age.